Determinants of the Financial Impact of Orphan Drugs in Italy: Differences Between Expected and Observed Pharmaceutical Expenditure
The actual expenditure for orphan drugs aligns with the expected post-negotiation. Yet, innovative orphan drugs exhibit a higher actual expenditure than estimated, suggesting the market values their added therapeutic value or the actual therapeutic need they meet, and configuring innovativeness status as the main determinant of the orphan drugs financial impact in the multiple regression analysis.
Authors
- Federica Romano (ORCID: https://orcid.org/0000-0002-5172-299X)
- Angelica Carletto (ORCID: https://orcid.org/0000-0002-2094-1946)
- Pierluigi Russo (ORCID: https://orcid.org/0000-0003-4881-5703)
- Paolo Sciattella (ORCID: https://orcid.org/0000-0002-8364-1895)
- Matteo Zanuzzi
- Filippo Rumi (ORCID: https://orcid.org/0000-0003-0094-0302)
- Americo Cicchetti (ORCID: https://orcid.org/0000-0002-4633-9195)
- Annalisa Sammarco (ORCID: https://orcid.org/0000-0002-4361-8076)
- Francesco Saverio Mennini
Institutions
- Università Cattolica del Sacro Cuore (IT)
- University of Rome Tor Vergata (IT)
- Ministero della Salute (IT)
- Italian Medicines Agency (IT)
Publication Details
- Journal
- Drugs - Real World Outcomes
- Published
- 2024-12-07
- DOI
- https://doi.org/10.1007/s40801-024-00463-w
- Citations
- 1
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 1.13